ArticleMolecular pharmaceutics2014
Biodistribution and in vivo activities of tumor-associated macrophage-targeting nanoparticles incorporated with doxorubicin.
Article in Molecular pharmaceutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 99 citations in OpenAlex.
- Systematic Review of Cancer Targeting by Nanoparticles Revealed a Global Association between Accumulation in Tumors and Spleen.International journal of molecular sciences · 2021Pooled it
- Perfluorocarbon nanodroplets are cytocompatible with osteoblast-lineage cells and modulate in vitro osteoclastogenesis differentially in normoxia and hypoxia.Scientific reports · 2026Article
- Targeting Tumor-Associated Macrophages to Reshape the Immuno-Mechanical Landscape: Molecular Mechanisms and Therapeutic Strategies.International journal of biological sciences · 2026Review
- PEGylated PLGA Nanoformulations For Effective Immunomodulatory Actors In Non-Small Cell Lung Cancer.International journal of nanomedicine · 2026Review
- Bioinspired and Biomimetic Nanocarriers: Advances in Exosomes and Cell-Membrane-Coated Systems for Therapeutic Applications.International journal of nanomedicine · 2026Review
- Development and optimisation of Polyelectrolyte Complex Nanoparticles Loaded with Sorafenib by Central Composite Design (CCD): In Vitro and In Vivo Studies for the Treatment of Triple Negative Breast Cancer.Pharmaceutical research · 2025Article
- Functional Polarization of Liver Macrophages by Glyco Gold Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- IgM has a better relative distribution in inflammation sites and tumor tissues than IgG.Journal of nanobiotechnology · 2025Article
- Enabling tumor-specific drug delivery by targeting the Warburg effect of cancer.Cell reports. Medicine · 2025Article
- Emerging macrophage-based therapies for cancer: a review of preclinical and clinical advances.Frontiers in immunology · 2025Review
- Targeting TAMs & CAFs in melanoma: New approaches to tumor microenvironment therapy.Oncology research · 2025Review
- Exploring the landscape of Lipid Nanoparticles (LNPs): A comprehensive review of LNPs types and biological sources of lipids.International journal of pharmaceutics: X · 2024Review
- Tumor-associated macrophages as a potential therapeutic target in thyroid cancers.Cancer immunology, immunotherapy : CII · 2023Review
- Effect of nanoparticle size on their distribution and retention in chronic inflammation sites.Discover nano · 2023Article
- Mannose-modified hyaluronic acid nanocapsules for the targeting of tumor-associated macrophages.Drug delivery and translational research · 2023Article
- Tumor-associated macrophages in nanomaterial-based anti-tumor therapy: as target spots or delivery platforms.Frontiers in bioengineering and biotechnology · 2023Review
- TAM-targeted reeducation for enhanced cancer immunotherapy: Mechanism and recent progress.Frontiers in oncology · 2022Review
- Functionalized Nanoparticles Targeting Tumor-Associated Macrophages as Cancer Therapy.Pharmaceutics · 2021Review
- Drug delivery carriers with therapeutic functions.Advanced drug delivery reviews · 2021Review
- Novel Anthracycline Utorubicin for Cancer Therapy.Angewandte Chemie (Weinheim an der Bergstrasse, Germany) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
Tumor-associated macrophages (TAMs) are increasingly considered a viable target for tumor imaging and therapy. Previously, we reported that innovative surface-functionalization of nanoparticles may help target them to TAMs. In this report, using poly(lactic-co-glycolic) acid (PLGA) nanoparticles incorporated with doxorubicin (DOX) (DOX-NPs), we studied the effect of surface-modification of the nanoparticles with mannose and/or acid-sensitive sheddable polyethylene glycol (PEG) on the biodistribution of DOX and the uptake of DOX by TAMs in tumor-bearing mice. We demonstrated that surface-modification of the DOX-NPs with both mannose and acid-sensitive sheddable PEG significantly increased the accumulation of DOX in tumors, enhanced the uptake of the DOX by TAMs, but decreased the distribution of DOX in mononuclear phagocyte system (MPS), such as liver. We also confirmed that the acid-sensitive sheddable PEGylated, mannose-modified DOX-nanoparticles (DOX-AS-M-NPs) targeted TAMs because depletion of TAMs in tumor-bearing mice significantly decreased the accumulation of DOX in tumor tissues. Furthermore, in a B16-F10 tumor-bearing mouse model, we showed that the DOX-AS-M-NPs were significantly more effective than free DOX in controlling tumor growth but had only minimum effect on the macrophage population in mouse liver and spleen. The AS-M-NPs are promising in targeting cytotoxic or macrophage-modulating agents into tumors to improve tumor therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.